Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) EPS (Weighted Average and Diluted) (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.33 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 13.79% year-over-year to -$0.33, compared with a TTM value of -$2.05 through Sep 2025, up 20.54%, and an annual FY2024 reading of -$2.57, up 5.17% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.33 for Q3 2025 at Xenetic Biosciences, up from -$0.45 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.29 in Q3 2024 and bottomed at -$0.82 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.62, with a median of -$0.68 recorded in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 57.97% in 2024, while the deepest fall reached 29.26% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.82 in 2023, then increased by 17.24% to -$0.68 in 2024, then soared by 51.47% to -$0.33 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for XBIO at -$0.33 in Q3 2025, -$0.45 in Q2 2025, and -$0.59 in Q1 2025.